ImaginAb and the GSK Clinical Imaging Centre (CIC) (part of the GlaxoSmithKline Group of companies) have signed two research collaboration agreements to re-engineer a therapeutic antibody into recombinant antibody fragments for diagnostic imaging currently under development by GSK in the field of oncology.
Christian Behrenbruch, CEO of ImaginAb, said: “ImaginAb is pleased to have formalised this collaboration with the GSK CIC. Not only does GSK have an excellent biologics pipeline, but the company’s large-scale commitment to diagnostic imaging is extremely impressive and this particular collaboration is a natural fit with ImaginAb’s technology platform.”
Paul Matthews, vice president for translational research and head of the GSK CIC, said: “Our collaboration with ImaginAb for antibody fragment imaging is part of our further exploration of the role of biologics in diagnostic imaging with Positron Emission Tomography, an increasingly important clinical modality and a tool that is of significant interest to pharma in the discovery and development of new therapeutics.
“As we expand and develop our pipeline, technologies such as ImaginAb’s recombinant antibody fragment engineering technology may help us to look at targeted molecular therapeutics in new ways.”
Additionally, GlaxoSmithKline (GSK), Imperial College London (ICL) and the Medical Research Centre (MRC) have established a research collaboration in medical imaging, creating a Clinical Imaging Centre (CIC) based at Hammersmith Hospital in West London.